BRAF and low grade glioma: For example, several studies on pediatric patients with BRAF- or NF1-altered progressive or recurrent low-grade gliomas (LGG), including PAs, reported on promising clinical signals for targeted treatments with BRAF or MEK inhibitors when compared to control patients receiving the standard-of-care [4, 10, 13].